Refractory lactotroph adenomas.
Urwyler, Sandrine A Karavitaki, Niki
Urwyler, Sandrine A
Karavitaki, Niki
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-03-16
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
A small subset of lactotroph adenomas is resistant to dopamine agonists (DA) and can also demonstrate aggressive or even malignant behavior. The implicated mechanisms are not clearly defined. Management can be challenging and requires a multidisciplinary approach. In DA resistant prolactinomas, switching to another DA could be the first option to consider. Further strategies include surgery and radiotherapy used alone or in combination. In cases of aggressive or malignant prolactinomas, temozolomide could be offered. Immune checkpoint inhibitors have been also recently proposed as an alternative approach. The place of other treatments (e.g., metformin, selective estrogen modulators, somatostatin analogues, tyrosine kinase inhibitors, inhibitors of mammalian target of rapamycin and peptide radio-receptor therapy) remains to be carefully assessed.
Citation
Urwyler SA, Karavitaki N. Refractory lactotroph adenomas. Pituitary. 2023 Jun;26(3):273-277. doi: 10.1007/s11102-023-01305-8. Epub 2023 Mar 16
Type
Article